TruScreen Group has met its FY2026 revenue guidance with a 41% jump in product sales, while investing heavily in new markets and pursuing a major UNITAID funding bid that could reshape its medium-term outlook.
- FY2026 product sales revenue rose 41% to NZ$2.4 million
- Total revenue slightly exceeded guidance at NZ$2.8 million
- Unaudited loss of NZ$2.2 million reflects expansion costs
- Distributor network expanded in Uzbekistan, India, Indonesia, and Africa
- Consortium bid for up to US$57.3 million UNITAID funding underway
Revenue Growth Supported by Wider Market Reach
TruScreen Group Limited (NZX:TRU) has confirmed it met its FY2026 revenue guidance, with product sales hitting approximately NZ$2.4 million, a 41% increase on the prior year. Total revenue came in slightly above expectations at NZ$2.8 million, marking a 29% rise from FY2025. This growth reflects the company’s success in broadening its geographic footprint, spreading revenue across a more diverse set of countries.
Losses Persist Amid Strategic Investments
Despite the revenue gains, TruScreen is expected to report an unaudited loss of around NZ$2.2 million for FY2026, consistent with the previous year. The loss stems largely from increased market access development costs as the company invests in expanding its distributor network across Uzbekistan, India, Indonesia, and select African markets. These moves are designed to build the critical mass necessary for sustainable profitability over the medium term, a strategy that requires upfront spending to establish presence and adoption.
Clinical Validation Spurs New Opportunities
Positive clinical validation continues to underpin TruScreen’s market appeal. The February 2026 publication of peer-reviewed results by Germany’s BMC Cancer, based on a 15,000-patient study conducted by the Chinese Obstetricians and Gynaecologists Association (COGA), has generated fresh interest in TruScreen’s AI-enabled cervical cancer screening technology. This validation adds credibility to the device’s real-time detection capabilities, which bypass the need for tissue sampling and complex lab infrastructure.
Pursuit of Major UNITAID Funding
Building on its ongoing success with Zimbabwe’s National Aids Council cervical cancer screening programme, TruScreen has joined a consortium submitting three applications to UNITAID for funding aligned with WHO’s 2030 90-70-90 cervical cancer milestones. The potential funding pool totals US$57.3 million over three years, with TruScreen positioned as consortium lead for potential revenue of up to US$18.4 million. The outcome of these applications is expected around November 2026, representing a significant possible catalyst for the company.
Global Regulatory Footprint and Device Adoption
TruScreen’s device, TruScreen Ultra®, is CE marked and registered for clinical use in multiple jurisdictions including Australia, UK, China, Saudi Arabia, Russia, and Mexico. It has Ministry of Health approvals in Vietnam, Israel, Ukraine, and the Philippines, and distributors in 29 countries. The company’s manufacturing base in China supports its largest market, where over 200 devices have been installed. In FY2024 alone, more than 200,000 examinations were performed using TruScreen’s technology, underscoring its growing adoption.
Bottom Line?
TruScreen’s FY2026 results confirm the costs of expansion but also highlight growing traction and a potentially transformative funding opportunity that could reshape its financial trajectory.
Questions in the middle?
- Will the UNITAID funding applications succeed and how will that impact TruScreen’s revenue profile?
- How quickly can TruScreen convert its expanded distributor network into sustained profitability?
- What are the risks if clinical validation momentum slows or competitors advance similar AI screening technologies?